MC
UTHR icon

Miles Capital’s United Therapeutics UTHR Stock Holding History

Miles Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,898
Closed -$246K – 228
2017
Q2 		$246K Hold
1,898
– – 0.13% 142
2017
Q1 		$257K Sell
1,898
-934
-33% -$141K 0.14% 129
2016
Q4 		$406K Hold
2,832
– – 0.25% 63
2016
Q3 		$334K Buy
+2,832
New +$340K 0.23% 71

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Miles Capital's UTHR Position: Q3 2017 in Review

Miles Capital sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 1,898 shares — an estimated $246K sold.

Miles Capital first reported a position in UTHR in Q3 2016 and held it in 4 quarters. The position peaked at $406K in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Miles Capital reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Miles Capital sold 1,898 United Therapeutics shares in Q3 2017, an estimated $246K.
  • Miles Capital first reported a position in United Therapeutics in Q3 2016 and held it in 4 quarters.
  • Miles Capital's United Therapeutics position peaked at $406K in Q4 2016.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Miles Capital's 13F filing for Q3 2017, filed 13 Nov 2017.